SUTURES
    1.
    发明公开
    SUTURES 审中-公开

    公开(公告)号:US20240157020A1

    公开(公告)日:2024-05-16

    申请号:US18550874

    申请日:2022-03-15

    IPC分类号: A61L17/00 A61L17/04 A61L17/12

    摘要: The invention relates to a suture thread material comprising at least one polymer and at least one eutectic mixture. The polymer can be a biocompatible polymer such as polycaprolactone or PLGA. The eutectic mixture may comprise maleic acid and an antibiotic such as metronidazole. Other eutectic mixtures can be used in suture thread materials to reduce SSis and/or to decrease pain and/or to increase lubricity of sutures. The invention also provides a method for the production of sutures with drug loadings, the method comprising the use of therapeutic deep eutectic solvent (THEDES) technology to significantly increase drug content in suture matrices.

    MINIATURE ANTENNA WITH OMNIDIRECTIONAL RADIATION FIELD

    公开(公告)号:US20230318186A1

    公开(公告)日:2023-10-05

    申请号:US18021671

    申请日:2021-08-16

    IPC分类号: H01Q9/04 H01Q13/10 H01Q1/48

    CPC分类号: H01Q9/0464 H01Q13/10 H01Q1/48

    摘要: An antenna comprises a planar radiating structure, a ground plane and a feed structure. The radiation structure comprises a plurality of slots arranged symmetrically in concentric rings around an inner portion of the radiating structure. The slots are arranged to create a meandering current path on the radiating structure. The antenna produces an omnidirectional, monopole-like radiation field, and is relatively small with relatively high performance making it suitable for use in a wide variety of applications including those with challenging environments.

    A PEPTIDE FOR THE DELIVERY OF ANIONIC MATERIALS

    公开(公告)号:US20220389059A1

    公开(公告)日:2022-12-08

    申请号:US17437025

    申请日:2020-03-09

    IPC分类号: C07K7/08 C12N15/87 A61P35/00

    摘要: The present invention is directed to a peptide for the delivery of anionic materials, such as anionic therapeutic agents, across a biological barrier, and methods of use thereof. The invention relates to a peptide comprising, or consisting of: X-(Xaa1)a-(Xaa2)b-Y-(Xaa3)c-(Xaa4)d-Z, in which each of X and Z is independently selected from Asn, Cys, Gln, Gly, Ser, Thr and Tyr; in which one of Xaa1 and Xaa2 is His and the other of Xaa1 and Xaa2 is Arg; in which one of Xaa3 and Xaa4 is His and the other of Xaa3 and Xaa4 is Arg; in which the amino functional group of X is, optionally, acylated; in which the carboxylate functional group of Z is, optionally, amidated; in which Y is selected from Ala and Trp; in which each of a and d is independently 2 to 4; and each of b and c is independently 2 to 4, or a salt or amide thereof. The invention also relates to a peptide for use in inducing an immune response in a subject in need thereof or a method for inducing an immune response in a subject comprising the administration of the peptide to a subject in need thereof. The invention also relates to a peptide for use in the treatment and/or prophylaxis of an infection, cancer, wounds in a subject in need thereof or a method for the treatment and/or prophylaxis of an infection, cancer, wounds comprising the administration of the peptide of the first aspect of the invention to a subject in need thereof.

    Ocular compositions
    4.
    发明授权

    公开(公告)号:US11504340B2

    公开(公告)日:2022-11-22

    申请号:US16612181

    申请日:2018-05-10

    摘要: The invention provides methods of making microparticle and nanoparticle ocular implants from a compositions comprising: 99 to 60% (w/w) of a photopolymerizable composition selected from the group of fragments or monomers consisting of polyalkylene glycol diacrylate and polyalkylene glycol dimethacrylate, wherein the photopolymerizable composition has a molecular weight in the range of 100 to 20,000 Dalton; a biodegradable polymer selected from the group consisting of aliphatic polyester-based polyurethanes, polylactides, polycaprolactones, polyorthoesters and mixtures, copolymers, and block copolymers thereof; a photoinitiator; and a therapeutic agent.

    Methods and kits for the detection of DNA

    公开(公告)号:US11078524B2

    公开(公告)日:2021-08-03

    申请号:US16557308

    申请日:2019-08-30

    IPC分类号: C12Q1/6816

    摘要: The invention relates to methods and kits for DNA The method comprises a) contacting the sample with a plurality of metal nanoparticles functionalised with one or more RNA probes; b) forming a heteroduplex between the target DNA and RNA probe on an RNA-functionalised metal nanoparticle; c) contacting the heteroduplex of target DNA and RNA probe on the RNA-functionalised metal nanoparticle with an enzyme that cleaves RNA in a DNA-RNA heteroduplex thereby releasing the target DNA; d) repeating steps (b) and (c) until all, or substantially all, of the RNA probes on the plurality of RNA-functionalised metal nanoparticles have been cleaved from the metal nanoparticles; and e) aggregating the metal nanoparticles from which all, or substantially all, of the RNA probes have been cleaved, thereby indicating the presence of the target DNA.

    Methods and kits for the detection of DNA

    公开(公告)号:US10400268B2

    公开(公告)日:2019-09-03

    申请号:US15341162

    申请日:2016-11-02

    IPC分类号: C12Q1/6816

    摘要: The present invention is related to methods and kits for the detection of deoxyribonucleic acid (DNA), in particular pathogenic microbial DNA, which provide more simple and sensitive detection of DNA compared to similar methods and kits known in the art. The method comprises a) contacting the sample with a plurality of metal nanoparticles functionalized with one or more ribonucleic acid (RNA) probes; b) forming a heteroduplex between the target DNA and RNA probe on an RNA-functionalized metal nanoparticle; c) contacting the heteroduplex of target DNA and RNA probe on the RNA-functionalized metal nanoparticle with an enzyme that cleaves RNA in a DNA-RNA heteroduplex thereby releasing the target DNA; d) repeating steps (b) and (c) until all, or substantially all, of the RNA probes on the plurality of RNA-functionalized metal nanoparticles have been cleaved from the metal nanoparticles; and e) aggregating the metal nanoparticles from which all, or substantially all, of the RNA probes have been cleaved, thereby indicating the presence of the target DNA.